ReviewNature reviews. Drug discovery2011
Anti-inflammatory therapeutics for the treatment of atherosclerosis.
Review in Nature reviews. Drug discovery, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 115 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
115 citing papers in PubMed, 1 synthesis or guideline pooled it, 304 citations in OpenAlex.
- Exploring global research trends in Chinese medicine for atherosclerosis: a bibliometric study 2012-2023.Frontiers in cardiovascular medicine · 2024Pooled it
- Anti-inflammatory agents in atherosclerosis-and a need for reform: Extraordinary claims require extraordinary evidence.Journal of internal medicine · 2026Article
- A Nomogram Based on the Castelli Risk Index for Predicting Prognosis in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: A Cohort Study.Immunity, inflammation and disease · 2026Article
- Targeting pathological chemokines in CVD: the role of saffron on CCL2 and CXCL8.Molecular biology reports · 2026Review
- TNFSF13 Drives Atherosclerosis Progression by Targeting Macrophage Senescence.International journal of medical sciences · 2026Article
- Occludin-mediated barrier dysfunction and its role in cardiovascular and cerebrovascular pathogenesis.Frontiers in cardiovascular medicine · 2026Review
- Prodrug Strategies in Atherosclerosis: Targeted Delivery and Therapeutic Advances.Cardiovascular therapeutics · 2026Review
- Targeted Anti-Inflammatory Therapy in Cardiovascular Events: Challenges and Opportunities.Journal of clinical hypertension (Greenwich, Conn.) · 2025Review
- Enhanced lymphocyte infiltration in the liver of LDL receptor and Myeloid Differentiation 1 double knockout mice on high fat diet.Scientific reports · 2025Article
- Down-regulation of ATP8B2 in Foam Cells Inhibits Autophagic Flux and ox-LDL Degradation in Atherosclerosis.Cell biochemistry and biophysics · 2025Article
- Interpretable machine learning leverages proteomics to improve cardiovascular disease risk prediction and biomarker identification.Communications medicine · 2025Article
- The Role of TLRs in Obesity and Its Related Metabolic Disorders.International journal of molecular sciences · 2025Review
- A Synthetic Nanoparticle to Mimic High-Density Lipoprotein for Reverse Cholesterol Transport.Methods in molecular biology (Clifton, N.J.) · 2025Article
- Anti-Inflammatory Potential of 3-Hydroxy-β-Ionone fromMolecules (Basel, Switzerland) · 2024Article
- Exploring the Landscape of Anti-Inflammatory Trials: A Comprehensive Review of Strategies for Targeting Inflammation in Acute Myocardial Infraction.Biomedicines · 2024Review
- Two sides of the same coin: Non-alcoholic fatty liver disease and atherosclerosis.Vascular pharmacology · 2024Review
- PLGA-Chitosan Encapsulated IL-10 Nanoparticles Modulate Chlamydia Inflammation in Mice.International journal of nanomedicine · 2024Article
- Reversal of atherosclerosis by restoration of vascular copper homeostasis.Experimental biology and medicine (Maywood, N.J.) · 2024Review
- Addressing the Missing Links in Cardiovascular Aging.Clinical interventions in aging · 2024Review
- Review
55 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
Atherosclerosis is the primary cause of heart disease and stroke and is thus the underlying pathology of the leading causes of death in the western world. Although risk can be reduced by lowering lipid levels, the equally important contribution of inflammation to the development of cardiovascular disease is not adequately addressed by existing therapies. Here, we summarize the evidence supporting a role for inflammation in the pathogenesis of atherosclerosis, discuss agents that are currently in the clinic and provide a perspective on the challenges faced in the development of drugs that target vascular inflammation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.